

## **Imugene's key HER-Vaxx patent granted in Europe**

---

- **Core EU patent granted in pivotal pharmaceutical market**
- **Patent provides method of composition and method of use protection to 2030**

**Melbourne, Australia, 18 December 2015:** Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, has received a Notice of Grant from the European Patent Office for Patent Application 10744895.3 (granted patent no. 2467155), which protects its HER-Vaxx cancer immunotherapy, currently in development for gastric cancer.

The patent titled "Multiepitope Vaccine for HER2/Neu-associated Cancers" protects the method of composition and method of use to 2030 of Imugene's HER-Vaxx for the generation of a therapeutic antibody response against HER-2/neu<sup>1</sup>.

HER-Vaxx is a proprietary therapeutic cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu, the same biomarker targeted by the \$US6.9 billion per annum drug Herceptin®. HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase Ib/II study in gastric cancer.

"The strengthening of our patent portfolio in Europe is an important milestone and underpins our commercialisation strategy," said Ms Leslie Chong, Chief Operating Officer of Imugene.

Gastric or stomach cancer is the second most common cause of cancer-related death in the world and the fourth most commonly diagnosed cancer, with over 1 million new cases diagnosed each year. In the EU, where gastric cancer incidence is lower than in Asia and other emerging regions, there are still around 50,000 new cases each year and 35,000 gastric cancer-related deaths, represented a sizeable area of unmet medical need with Imugene believes HER-Vaxx can serve<sup>2</sup>.

### **About Imugene and HER-Vaxx**

Imugene (ASX: IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Imugene's lead product is HER-Vaxx, a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria, is a peptide vaccine constructed from various B cell epitopes of HER-2/neu. It has been shown in pre-clinical work and in one Phase I study to stimulate a potent polyclonal antibody response to HER-2/neu, a known and validated cancer target. HER-Vaxx's successful Phase I study was in patients with breast cancer and the next stage of development will be a Phase Ib/II study in patients with gastric cancer. For further information, please visit [www.imugene.com](http://www.imugene.com). Sign up to follow @TeamImugene on Twitter at <http://www.twitter.com/TeamImugene>.

---

<sup>1</sup> See WO/2011/020604, priority date 18 August 2009.

<sup>2</sup> Source: EUCAN estimates for 2012.

**For further information please contact:**

**Imugene:**

Leslie Chong, Chief Operating Officer

Tel: +61 458 040 433 (Australia), leslie.chong [at]imugene.com

Paul Hopper, Executive Chairman

Tel: +61 406 671 515 (Australia), receptogen[at]earthlink.net

**Media:**

Rudi Michelson, Monsoon Communications

Tel: +61 3 9620 3333, rudim[at]monsoon.com.au